Get the Stockscreener App
1.46
1.39%
0.02
Pliant Therapeutics Inc stock is traded at $1.46, with a volume of 756.69K.
It is up +1.39% in the last 24 hours and down -14.12% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.44
Open:
$1.43
24h Volume:
756.69K
Relative Volume:
0.33
Market Cap:
$86.96M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4725
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+16.33%
1M Performance:
-14.12%
6M Performance:
-90.05%
1Y Performance:
-88.65%
1-Day Range:
$1.41
$1.5066
1-Week Range:
$1.23
$1.5066
52-Week Range:
$1.1001
$16.52
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.46 | 86.96M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - TradingView
Pliant Therapeutics stock hits 52-week low at $1.2 amid sharp decline - Investing.com
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Major Breakthrough: Pliant Reveals Latest Bexotegrast Research Data in Three Key Presentations - Stock Titan
Pliant Therapeutics Announces Upcoming Presentations at the - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - ACCESS Newswire
Pliant Therapeutics: An Activist On Deck - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
PLRX stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Canada
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - MSN
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics – PLRX - menafn
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire Inc.
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Pliant Therapeutics Inc - GuruFocus
Pliant discontinues Phase 2b/3 trial of IPF treatment bexotegrast - Pulmonary Fibrosis News
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com
Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright - Defense World
Pliant Therapeutics Announces Interim Phase 1 Data for - GlobeNewswire
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types - Benzinga
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Markets Insider
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial - Marketscreener.com
Breakthrough: New Cancer Drug Achieves 74% Tumor Reduction in Phase 1 Study - Stock Titan
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Yahoo Finance
Pliant Therapeutics adopts shareholder rights plan By Investing.com - Investing.com Australia
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com
Pliant Therapeutics adopts shareholder rights plan - Investing.com India
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - The Manila Times
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq
Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):